The price of CON is predicted to go up 4.65%, based on the high correlation periods with WSFS. The similarity of these two price pattern on the periods is 98.97%.
CON
WSFS
Up: 4.65%Similarity: 98.97%
CON Revenue Forecast
CON EPS Forecast
CON FAQs
What is bull’s view on CON?
CON stock has a bullish outlook with a price target of $25-$30, supported by recent analyst upgrades and acquisition news. BofA Securities raised its target to $25, citing improved Q4 estimates and strategic visibility from the Nova Medical Centers acquisition. RBC Capital remains optimistic with a $30 target, reflecting a 27% upside potential.
What is bear's view on CON?
CON stock currently trades at $19.29, with analysts projecting a 42.56% upside to $27.50. However, recent Q4 2024 results showed declining net income, and the acquisition of U.S. Occmed Holdings for $265M adds integration risks. Bearish sentiment arises from potential overvaluation concerns and execution challenges despite growth prospects.
What is CON revenue forecast for next quarter?
The market consensus for CON's revenue in the upcoming quarter is projected to be approximately $491.826M USD.
What is CON eps forecast for next quarter?
The market consensus for CON's eps in the upcoming quarter is projected to be approximately $0.305 USD.
BofA raised the firm's price target on Concentra to $25 from $24 and keeps a Buy rating on the shares after the company announced an agreement to acquire Nova Medical Centers for $265M, pre-announced Q4 results, and provided 2025 guide that was roughly in line with consensus excluding the Nova deal contribution. The firm raised its estimates for a better Q4 and the deal and raised its multiple given the increased visibility into estimates.